Seeking Alpha
Profile| Send Message|
( followers)  

<< Return to Part 1

This is a continuation of my previous article on biotechnology stocks to watch ahead of ASCO 2012. In this article, I cover the second set of stocks that are presenting at ASCO 2012. Biotech stocks are high risk/reward stocks, and therefore considerable analysis is required before trading. Use this list as a potential starting point for your analysis.

1. ImmunoGen (NASDAQ:IMGN): ImmunoGen engages in the research and development of targeted therapeutics for the treatment of cancer using cancer biology, monoclonal antibodies, and highly potent cell-killing agents. The company develops its products using its Targeted Antibody Payload ((NYSE:TAP)) technology. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare, Biotest, Lilly, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group.

On May 16, 2012, ImmunoGen announced that there will be four presentations at the upcoming ASCO 2012 Annual Meeting on compounds that utilize the Company's Targeted Antibody Payload technology. Of particular note, the findings in the trastuzumab emtansine Emilia Phase III trial will be featured in an ASCO plenary session on June 3, and findings with SAR3419 administered with its Phase II dosing schedule will be reported in a poster presentation on June 4, 2012.

The details of the abstracts and schedule can be found here.

ImmunoGen has a market cap of $1.12 billion and is currently trading around $14.50 with a 52-week range of $9.17 to $16.20. The stock has 25.22% price performance for 2012.

2. Nektar Therapeutics (NASDAQ:NKTR): Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's (OTCPK:AFFY) Omontys for anemia, UCB's Cimzia for Crohn's disease and rheumatoid arthritis, Roche's Pegasys for hepatitis C and Amgen's (NASDAQ:AMGN) Neulasta for neutropenia.

Nektar will present two sessions about etirinotecan pegol (NKTR-102 ) in the upcoming ASCO 2012, including the sessions "Trials in Progress Session" on June 2, 2012, from 8:00 a.m. to 12:00 p.m. CT and "General Poster Session: Gynecologic Cancer" on June 3, from 8:00 a.m. to 12:00 p.m. CT.

The details of the abstracts and schedule can be found here.

Nektar Therapeutics has a market cap of $798.83 million and is currently trading around $6.97 with a 52-week range of $4.07 to $9.71. The stock has 24.46% price performance for 2012.

3. NewLink Genetics (NASDAQ:NLNK): NewLink Genetics operates as a biopharmaceutical company. It focuses on discovering, developing, and commercializing immunotherapeutic products to enhance cancer treatment options for patients and physicians. Its product portfolio includes biologic and small-molecule immunotherapy product candidates based on proprietary HyperAcute immunotherapy technology for the treatment of various oncology indications.

On April 11, 2012, NewLink Genetics announced that data from its HyperAcute Pancreas immunotherapy and its HyperAcute® Lung immunotherapy as well as its D-1MT IDO pathway inhibitor will be presented at the upcoming ASCO 2012 Annual Meeting.

The details of the abstracts and schedule can be found here.

NewLink has a market cap of $237.71 million and is currently trading around $11.50 with a 52-week range of $6.25 to $12.80. The stock has 63.35% price performance for 2012.

4. Seattle Genetics (NASDAQ:SGEN): Seattle Genetics is a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, Adcetris, has accelerated approval form the U.S. FDA in August 2011. In addition, Seattle Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott (NYSE:ABT), Bayer, Celldex Therapeutics (NASDAQ:CLDX), Daiichi Sankyo, Genentech , GlaxoSmithKline (NYSE:GSK), Millennium, Pfizer (NYSE:PFE) and Progenics (NASDAQ:PGNX), as well as ADC co-development agreements with Agensys, an affiliate of Astellas (OTCPK:ALPMF), and Genmab.

On May. 16, 2012, Seattle Genetics announced that data from two of its antibody-drug conjugate (ADC) programs, Adcetris (brentuximab vedotin) and ASG-5ME, will be presented at the ASCO 2012 Annual Meeting.

A summary of the company's poster presentations and full abstracts can be found here.

Seattle Genetics has a market cap of $2.39 billion and is currently trading around $20.44 with a 52-week range of $12.29 to $22.40. The stock has 22.25% price performance for 2012.

5. Genomic Health (NASDAQ:GHDX): Genomic Health, a molecular diagnostics company, engages in the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor.

On May 16, 2012. Genomic Health announced that results from 18 separate studies covering breast, colon and prostate cancers will be presented at the ASCO 2012 Annual Meeting, reflecting the company's ongoing commitment to the research, development and delivery of innovative diagnostic tests to help individualize cancer treatment decisions.

The details of the abstracts and schedule can be found here.

Genomic Health has a market cap of $997.66 million and is currently trading around $33.2 with a 52-week range of $19.00 to $35.00. The stock has 30.76% price performance for 2012.

6. Onyx Pharmaceuticals (NASDAQ:ONXX): Onyx Pharmaceuticals, a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. The company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition.

Onyx Pharmaceuticals will present its data at the ASCO 2012 Annual meeting to demonstrate its innovative cancer treatment options including, Nexavar (sorafenib) tablets, Kyprolis (proposed trademark for carfilzomib) and regorafenib, a Bayer-owned compound.

The details of the abstracts and schedule can be found here.

Onyx Pharmaceuticals has a market cap of $2.83 billion and is currently trading around $46.60 with a 52-week range of $27.17 to $47.80. The stock has 6.03% price performance for 2012.

Some of the data is sourced from Google Finance, Yahoo Finance, Finviz, Fidelity and investors site.

Disclaimer: I am not a registered investment advisor and do not provide specific investment advice. The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. It is up to investors to make the correct decision after necessary research.

Continue to Part 3 >>

Source: Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 2